Skip to main content

Biogelx

MaterialsLanarkshire, United KingdomFounded 2012· One of 884 Materials companies tracked by AMPulse

Develops and supplies synthetic peptide hydrogels and bioinks for 3D bioprinting and cell culture, enabling in-vivo-like tissue models for drug discovery and regenerative medicine.

CEO / Founder
Alison Clayton
Team Size
11-50
Stage
Active
Total Funding
$1M
Latest Round
Grant
Key Investors
Scottish Enterprise; Innovate UK; European Regional Development Fund

Technology & Products

Key Products

Biogelx™-S (standard hydrogel); Biogelx™-Inks (bioinks for 3D bioprinting); Peptide hydrogels for 3D cell culture

Technological Advantage

Proprietary peptide technology enables precise control over hydrogel properties (e.g., stiffness, porosity) to emulate various tissue types, validated in 3D bioprinting applications; advantage is defensible via trade secrets and potential patents.

Differentiation

Value Proposition

Provides reproducible, scalable, and tunable synthetic hydrogels that mimic native extracellular matrix, reducing reliance on animal-derived materials and improving predictive accuracy of in-vitro models for faster drug development.

How They Differentiate

Focuses on synthetic, peptide-based hydrogels (vs. animal-derived alternatives like Matrigel) with tunable mechanical properties for specific tissue modeling; offers bioinks compatible with extrusion bioprinting, emphasizing reproducibility and scalability for research applications.

Market & Competition

Target Customers

Academic researchers, pharmaceutical companies, biotechnology SMEs, tissue engineering labs

Industry Verticals

Pharmaceuticals; Biotechnology; Academic Research; Regenerative Medicine

Competitors

Cellink (BICO Group); VivoSim Labs (formerly Organovo); Advanced BioMatrix

Growth & Milestones

Growth Metrics

Supplied materials to over 100 research institutions globally; 300% revenue growth from 2019 to 2021; Expanded to US market in 2020

Major Milestones

2013: Won Royal Society of Chemistry’s Emerging Technologies competition, gaining GSK mentorship; 2016+: Global reputation in 2D/3D cell culture; peptide bioinks commercialized for bioprinting

Notable Customers

University of Glasgow; University of Strathclyde; AstraZeneca; GlaxoSmithKline